HT
RGLS

HAP Trading’s Regulus Therapeutics RGLS Stock Holding History

HAP Trading’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,390
Closed -$47K – 2706
2021
Q2 		$47K Buy
+1,390
New +$15.5K ﹤0.01% 1494

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HAP Trading's RGLS Position: Q2 2015 in Review

HAP Trading sold out of Regulus Therapeutics (RGLS) in Q2 2015, closing a stake of 210 shares — an estimated $339K sold.

HAP Trading first reported a position in RGLS in Q4 2014 and held it in 2 quarters. The position peaked at $691K in Q4 2014. 92 funds tracked by Wall St. Rank hold RGLS as of Q2 2015.

  • HAP Trading reported no remaining Regulus Therapeutics position as of Q2 2015 after selling out during the quarter.
  • HAP Trading sold 210 Regulus Therapeutics shares in Q2 2015, an estimated $339K.
  • HAP Trading first reported a position in Regulus Therapeutics in Q4 2014 and held it in 2 quarters.
  • HAP Trading's Regulus Therapeutics position peaked at $691K in Q4 2014.
  • 92 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2015.

Based on HAP Trading's 13F filing for Q2 2015, filed 12 Aug 2015.